Hedström J, Kemppainen E, Andersén J, Jokela H, Puolakkainen P, Stenman U H
Department of Clinical Chemistry, University of Helsinki, Finland.
Am J Gastroenterol. 2001 Feb;96(2):424-30. doi: 10.1111/j.1572-0241.2001.03457.x.
The aim of the study was to compare the recently introduced laboratory markers trypsinogen-2 and trypsin-2-alpha1 antitrypsin complex (trypsin-2-AAT) in serum with lipase and amylase in the diagnostic and prognostic evaluation of patients with acute pancreatitis (AP).
The analytes were measured on admission in 64 consecutive patients with AP and in 30 controls with acute abdominal disease of extrapancreatic origin. Twenty-one patients had severe and 43 mild AP. As reference methods we used serum amylase and C-reactive protein.
In subjects with AP, elevated trypsinogen-2 values (> or = 90 microg/L) were observed in 63 patients (98%), trypsin-2-AAT values (> or = 12 microg/L) in 64 patients (100%), lipase values (> or = 200 U/L) in 64 patients (100%), and amylase values (> or = 300 IU/L) in 62 patients (97%). The diagnostic accuracy of the markers was evaluated by receiver operating characteristic (ROC) analysis. On admission, trypsinogen-2, trypsin-2-AAT, lipase, and amylase differentiated patients with AP from controls with high accuracy and ROC analyses showed similar areas under the ROC curves (AUC) for trypsinogen-2 (AUC 0.960), trypsin-2-AAT (0.948), lipase (AUC 0.947), and amylase (AUC 0.930). For differentiation between severe and mild AP, trypsin-2-AAT (AUC 0.805) was slightly better than trypsinogen-2 (AUC 0.792), and they were both clearly better than lipase (AUC 0.583), C-reactive protein (AUC 0.519), or amylase (AUC 0.632) (p < 0.05).
All the markers studied showed high accuracy for differentiating between AP and extrapancreatic diseases. However, trypsinogen-2 and trypsin-2-AAT displayed the best accuracy for predicting a severe AP already at admission, which makes these markers superior for clinical purposes.
本研究旨在比较近期引入的血清中胰蛋白酶原-2和胰蛋白酶-2-α1抗胰蛋白酶复合物(胰蛋白酶-2-AAT)与脂肪酶和淀粉酶在急性胰腺炎(AP)患者诊断和预后评估中的作用。
对64例连续的AP患者及30例胰腺外源性急性腹部疾病对照患者入院时进行分析物检测。21例患者为重症AP,43例为轻症AP。我们采用血清淀粉酶和C反应蛋白作为参考方法。
在AP患者中,63例(98%)患者的胰蛋白酶原-2值升高(≥90μg/L),64例(100%)患者的胰蛋白酶-2-AAT值升高(≥12μg/L),64例(100%)患者的脂肪酶值升高(≥200U/L),62例(97%)患者的淀粉酶值升高(≥300IU/L)。通过受试者工作特征(ROC)分析评估标志物的诊断准确性。入院时,胰蛋白酶原-2、胰蛋白酶-2-AAT、脂肪酶和淀粉酶能高度准确地区分AP患者与对照患者,ROC分析显示胰蛋白酶原-2(AUC 0.960)、胰蛋白酶-2-AAT(0.948)、脂肪酶(AUC 0.947)和淀粉酶(AUC 0.930)的ROC曲线下面积(AUC)相似。对于区分重症和轻症AP,胰蛋白酶-2-AAT(AUC 0.805)略优于胰蛋白酶原-2(AUC 0.792),且两者均明显优于脂肪酶(AUC 0.583)、C反应蛋白(AUC 0.519)或淀粉酶(AUC 0.632)(p<0.05)。
所有研究的标志物在区分AP和胰腺外疾病方面均显示出高准确性。然而,胰蛋白酶原-2和胰蛋白酶-2-AAT在入院时预测重症AP的准确性最佳,这使得这些标志物在临床应用中更具优势。